Antibody–drug Conjugates: Using Monoclonal Antibodies for Delivery of Cytotoxic Payloads to Cancer Cells

• Pratt WB , RuddonRW, EnsmingerWD et al. Part 2. The Anticancer Drugs. Oxford University Press, UK 69–198 (1994).
   Google Scholar
• Scheinberg DA , RosenblatTL, JurcicJGet al. Antibodies. In: Chemotherapy and Biotherapy: Principles and Practice (Fifth Edition). Chabner BA, Longo DL (Eds). Wolters Kluwer/Lippincott Williams & Wilkins, Health, PA, USA 465–494 (2011).
   Google Scholar
• Boyiadzis M , FoonKA. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther.8(8), 1151–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Reichert JM . Monoclonal antibodies in the clinic. Nat. Biotechnol.19(9), 819–822 (2001).
   PubMed Web of Science ®Google Scholar
• Lambert JM . Antibody–maytansinoid conjugates: a new strategy for the treatment of cancer. Drugs Future35(6), 471–480 (2010).
   Web of Science ®Google Scholar
• Senter PD . Potent antibody–drug conjugates for cancer therapy. Curr. Opin. Chem. Biol.13 (3), 235–244 (2009).
   PubMed Web of Science ®Google Scholar
• Goldmacher VS , BlattlerWA, LambertJM, ChariRVJ. Immunotoxins and antibody–drug conjugates for cancer treatment. In: Biomedical Aspects of Drug Targeting. Torchilin V, Muzykantov V (Eds). 291–309, Kluwer Academic Publishers, MA, USA (2002).
   Google Scholar
• Chari RV . Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res.41(1), 98–107 (2008).
   PubMed Web of Science ®Google Scholar
• Ducry L , StumpB. Antibody–drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem.21(1), 5–13 (2010).
   PubMed Web of Science ®Google Scholar
• Kovtun YV , GoldmacherVS. Cell killing by antibody–drug conjugates. Cancer Lett.255(2), 232–240 (2007).
   PubMed Web of Science ®Google Scholar
• Carter PJ , SenterPD. Antibody–drug conjugates for cancer therapy. Cancer J.14(3), 154–169 (2008).
   PubMed Web of Science ®Google Scholar
• Vater AV , GoldmacherVS. Antibody–cytotoxic compound conjugates for oncology. In: Macromolecular Anticancer Therapeutics. Reddy LH, Couvreur P (Eds). Springer, NY, USA 331–369 (2009).
   Google Scholar
• Henry MD , WenS, SilvaMDet al. A prostate-specific membrane antigen-targeted monoclonal antibody–chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64(21), 7995–8001 (2004).
   PubMed Web of Science ®Google Scholar
• Ma D , HopfCE, MalewiczADet al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12(8), 2591–2596 (2006).
   PubMed Web of Science ®Google Scholar
• Galsky MD , EisenbergerM, Moore-CooperSet al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26(13), 2147–2154 (2008).
   PubMed Web of Science ®Google Scholar
• Pan C , TerrettJ, RaoCet al. Human antibody conjugates of potential utility for prostate cancer therapy: a comparison of MGBA conjugates with antibodies targeting a cell surface target (prostate-specific membrane antigen) and an extracellular matrix target (Mindin/RG-1). AACR Annual Meeting Abstracts4062 (2008).
   Google Scholar
• Beeram M , BurrisHA, ModiSet al. A Phase I study of trastuzumab–DM1, a first-in-class HER2 antibody–drug conjugate (ADC), given every 3 weeks to patients with HER2+ metastatic breast cancer. Am. Soc. Clin. Onc. Annu. Meet. Proc. (2008) (Abstract #1028).
   Google Scholar
• Burris HA , VukeljaS, RugoHSet al. A Phase II study of trastuzumab–DM1 (T–DM1), a HER2 antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer. ASCO Breast Cancer Symposium Proceedings (2008) (Abstract 155).
   Google Scholar
• Holden SN , BeeramM, KropIEet al. A Phase I study of weekly dosing of trastuzumab–DM1 (T–DM1) in patients with advanced HER2+ breast cancer. Am. Soc. Clin. Onc. Annu. Meet. Proc. (2008) (Abstract 1029).
   Google Scholar
• Press MF , Cordon-CardoC, SlamonDJ. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene5(7), 953–962 (1990).
   PubMed Web of Science ®Google Scholar
• Carter P , SmithL, RyanM. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr. Relat. Cancer11(4), 659–687 (2004).
   PubMed Web of Science ®Google Scholar
• Xie H , BlattlerWA. In vivo behavior of Antibody–drug conjugates for the targeted treatment of cancer. Expert Opin. Biol. Ther.6(3), 281–291 (2006).
   PubMed Web of Science ®Google Scholar
• Kononen J , BubendorfL, KallioniemiAet al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4(7), 844–847 (1998).
   PubMed Web of Science ®Google Scholar
• Kovtun YV , AudetteCA, YeYet al. Antibody–drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 66(6), 3214–3221 (2006).
   PubMed Web of Science ®Google Scholar
• Liu C , TadayoniBM, BourretLAet al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl Acad. Sci. USA 93 (16), 8618–8623 (1996).
   PubMed Web of Science ®Google Scholar
• Bhaskar V , LawDA, IbsenEet al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res. 63 (19), 6387–6394 (2003).
   PubMed Web of Science ®Google Scholar
• Walter RB , RadenBW, KamikuraDMet al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105 (3), 1295–1302 (2005).
   PubMed Web of Science ®Google Scholar
• Smith LM , NesterovaA, AlleySCet al. Potent cytotoxicity of an auristatin-containing antibody–drug conjugate targeting melanoma cells expressing melanotransferrin/p97. Mol. Cancer Ther. 5(6), 1474–1482 (2006).
   PubMed Web of Science ®Google Scholar
• Smith LM , NesterovaA, RyanMCet al. CD133/prominin-1 is a potential therapeutic target for antibody–drug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 99 (1), 100–109 (2008).
   PubMed Web of Science ®Google Scholar
• Oflazoglu E , StoneIJ, GordonKet al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 14(19), 6171–6180 (2008).
   PubMed Web of Science ®Google Scholar
• Ingle GS , ChanP, ElliottJMet al. High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19–drug conjugate. Br. J. Haematol. 140 (1), 46–58 (2008).
   PubMed Web of Science ®Google Scholar
• Polson AG , WilliamsM, GrayAMet al. Anti-CD22–MCC–DM1: an antibody–drug conjugate with a stable linker for the treatment of non-Hodgkin‘s lymphoma. Leukemia 24(9), 1566–1573 (2010).
   PubMed Web of Science ®Google Scholar
• Polson A . Antibody–drug conjugates for the treatment of non-Hodgkin‘s lymphoma. Presented at: The Drug Discovery and Development of Innovative Therapeutics Conference. Boston, MA, USA, 7 August 2008.
   Google Scholar
• Younes A , Forero-TorresA, BartlettNLet al. Objective responses in a Phase I dose-escalation study of SGN-35, a novel antibody–drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. Am. Soc. Clin. Onc. Annu. Meet. Proc. 8526 (2008).
   Google Scholar
• Harries M , SmithI. The development and clinical use of trastuzumab (Herceptin®). Endocr. Relat. Cancer.9 (2), 75–85 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD , LiG, DuggerDLet al. Targeting HER2-positive breastcancer with trastuzumab–DM1, an antibody–cytotoxic drug conjugate. Cancer Res. 68 (22), 9280–9290 (2008).
   PubMed Web of Science ®Google Scholar
• Krop I , LoRussoP, MillerKDet al. A Phase II study of trastuzumab–DM1 (T–DM1), a novel HER2 antibody–drug conjugate, in patients previously treated with lapatinib, trastuzumab, and chemotherapy. Presented at: The 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 12 December 2009. (Abstract 5090).
   Google Scholar
• Wahl AF , KlussmanK, ThompsonJDet al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects anti-tumor activity in models of Hodgkin‘s disease. Cancer Res. 62(13), 3736–3742 (2002).
   PubMed Web of Science ®Google Scholar
• Bartlett NL , YounesA, CarabasiMHet al. A Phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 111(4), 1848–1854 (2008).
   PubMed Web of Science ®Google Scholar
• Fanale M , BartlettNL, Forero-TorresAet al. The antibody–drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory cd30-positive lymphomas in a Phase I weekly dosing study. Presented at: The 51st ASH Annual Meeting. New Orleans, LA, USA, 5–8 December 2009 (Abstract 2731).
   Google Scholar
• Junttila TT , LiG, ParsonsKet al. Trastuzumab–DM1 (T–DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1090-x (2010) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Sievers EL , AppelbaumFR, SpielbergerRTet al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93(11), 3678–3684 (1999).
   PubMed Web of Science ®Google Scholar
• Arceci RJ , SandeJ, LangeBet al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 106(4), 1183–1188 (2005).
   PubMed Web of Science ®Google Scholar
• Sievers EL , LarsonRA, StadtmauerEAet al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19(13), 3244–3254 (2001).
   PubMed Web of Science ®Google Scholar
• Krop IE , BeeramM, ModiSet al. Phase I study of trastuzumab–DM1, an HER2 antibody–drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698–2704 (2010).
   PubMed Web of Science ®Google Scholar
• Teicher BA . Antibody–drug conjugate targets. Curr. Cancer Drug Targets9(8), 982–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307(5706), 58–62 (2005).
   PubMed Web of Science ®Google Scholar
• Wu Y , Cain-HomC, ChoyLet al. Therapeutic antibody targeting of individual notch receptors. Nature 464(7291), 1052–1057 (2010).
   PubMed Web of Science ®Google Scholar
• Mukherjee S , RichardsonAM, Rodriguez-CanalesJet al. Identification of EpCAM as a molecular target of prostate cancer stroma. Am. J. Pathol. 175(6), 2277–2287 (2009).
   PubMed Web of Science ®Google Scholar
• Hofmeister V , SchramaD, BeckerJC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother.57(1), 1–17 (2008).
   PubMed Web of Science ®Google Scholar
• Schliemann C , NeriD. Antibody-based vascular tumor targeting. Recent Results Cancer Res.180, 201–216 (2010).
   PubMedGoogle Scholar
• Minchinton AI , TannockIF. Drug penetration in solid tumours. Nat. Rev. Cancer6(8), 583–592 (2006).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Mahadevan D , Von Hoff DD. Tumor–stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther.6(4), 1186–1197 (2007).
   PubMed Web of Science ®Google Scholar
• Vater CA , ManningC, MillarHet al. Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. EORTC-NCI-AACR-2008. Molecular Targets and Cancer therapeutics. (2008) (Abstract #ENA-0399).
   Google Scholar
• Thompson DS , PatnaikA, BendellJCet al. A Phase I dose-escalation study of IMGN388 in patients with solid tumors. 28(15s) J. Clin. Oncol. (2010) (Abstract 3058).
   Google Scholar
• Ostermann E , Garin-ChesaP, HeiderKHet al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin. Cancer Res. 14(14), 4584–4592 (2008).
   PubMed Web of Science ®Google Scholar
• Terrett JA , DevasthaliV, PanCet al. Ptk7 as a direct and tumor stroma target in multiple solid malignancies. Presented at: The 99th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, USA, 11–15 April 2008 (Abstract #1526).
   Google Scholar
• Boman BM , WichaMS. Cancer stem cells: a step toward the cure. J. Clin. Oncol.26(17), 2795–2799 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto OK , PerezJF. Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis. Expert. Rev. Mol. Diagn.8(4), 387–393 (2008).
   PubMed Web of Science ®Google Scholar
• Clarke MF , DickJE, DirksPBet al. Cancer stem cells – perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66(19), 9339–9344 (2006).
   PubMedGoogle Scholar
• Bonnet D , DickJE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med.3(7), 730–737 (1997).
   PubMed Web of Science ®Google Scholar
• Gil J , StembalskaA, PeszKAet al. Cancer stem cells: the theory and perspectives in cancer therapy. J. Appl. Genet. 49(2), 193–199 (2008).
   PubMed Web of Science ®Google Scholar
• Jones RJ , MatsuiWH, SmithBD. Cancer stem cells: are we missing the target? J. Natl Cancer Inst.96(8), 583–585 (2004).
   PubMedGoogle Scholar
• Bao S , WuQ, McLendonREet al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120), 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Bao S , WuQ, SathornsumeteeSet al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66(16), 7843–7848 (2006).
   PubMed Web of Science ®Google Scholar
• Dylla SJ , BevigliaL, ParkIKet al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3(6), E2428 (2008).
   PubMed Web of Science ®Google Scholar
• Eyler CE , RichJN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol.26(17), 2839–2845 (2008).
   PubMed Web of Science ®Google Scholar
• Jin L , HopeKJ, ZhaiQet al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12(10), 1167–1174 (2006).
   PubMed Web of Science ®Google Scholar
• Hosen N , ParkCY, TatsumiNet al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA 104(26), 11008–11013 (2007).
   PubMed Web of Science ®Google Scholar
• Stabile H , MitolaS, MoroniEet al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood 109(5), 1834–1840 (2007).
   PubMed Web of Science ®Google Scholar
• Sneddon JB , ZhenHH, MontgomeryKet al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl Acad. Sci. USA 103(40), 14842–14847 (2006).
   PubMed Web of Science ®Google Scholar
• Piccirillo SG , ReynoldsBA, ZanettiNet al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444(7120), 761–765 (2006).
   PubMed Web of Science ®Google Scholar
• Namkoong H , ShinSM, KimHKet al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 6, 74 (2006).
   PubMed Web of Science ®Google Scholar
• Kohler G , MilsteinC. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature256(5517), 495–497 (1975).
   PubMed Web of Science ®Google Scholar
• Almagro JC , FranssonJ. Humanization of antibodies. Front. Biosci.13, 1619–1633 (2008).
   PubMed Web of Science ®Google Scholar
• Jones PT , DearPH, FooteJet al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321(6069), 522–525 (1986).
   PubMed Web of Science ®Google Scholar
• Roguska MA , PedersenJT, HenryAHet al. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng. 9(10), 895–904 (1996).
   PubMedGoogle Scholar
• Roguska MA , PedersenJT, KeddyCAet al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl Acad. Sci. USA 91(3), 969–973 (1994).
   PubMed Web of Science ®Google Scholar
• Hwang WY , FooteJ. Immunogenicity of engineered antibodies. Methods36(1), 3–10 (2005).
   PubMed Web of Science ®Google Scholar
• Roopenian DC , AkileshS. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol.7(9), 715–725 (2007).
   PubMed Web of Science ®Google Scholar
• Lonberg N . Human antibodies from transgenic animals. Nat. Biotechnol.23(9), 1117–1125 (2005).
   PubMed Web of Science ®Google Scholar
• Lonberg N . Fully human antibodies from transgenic mouse and phage display platforms. Curr. Opin. Immunol.20(4), 450–459 (2008).
   PubMed Web of Science ®Google Scholar
• Hoogenboom HR . Selecting and screening recombinant antibody libraries. Nat. Biotechnol.23(9), 1105–1116 (2005).
   PubMed Web of Science ®Google Scholar
• Kim SJ , ParkY, HongHJ. Antibody engineering for the development of therapeutic antibodies. Mol. Cells20(1), 17–29 (2005).
   PubMed Web of Science ®Google Scholar
• Carter PJ . Potent antibody therapeutics by design. Nat. Rev. Immunol.6(5), 343–357 (2006).
   PubMed Web of Science ®Google Scholar
• Mascelli MA , ZhouH, SweetRet al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J. Clin. Pharmacol. 47(5), 553–565 (2007).
   PubMed Web of Science ®Google Scholar
• McDonagh CF , KimKM, TurcottEet al. Engineered anti-CD70 antibody–drug conjugate with increased therapeutic index. Mol. Cancer Ther. 7(9), 2913–2923 (2008).
   PubMed Web of Science ®Google Scholar
• Strome SE , SausvilleEA, MannD. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist12(9), 1084–1095 (2007).
   PubMed Web of Science ®Google Scholar
• Fujimori K , CovellDG, FletcherJEet al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31(7), 1191–1198 (1990).
   PubMed Web of Science ®Google Scholar
• Adams GP , SchierR, McCallAMet al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61(12), 4750–4755 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt MM , WittrupKD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther.8(10), 2861–2871 (2009).
   PubMed Web of Science ®Google Scholar
• Jefferis R . Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther.7(9), 1401–1413 (2007).
   PubMed Web of Science ®Google Scholar
• Salfeld JG . Isotype selection in antibody engineering. Nat. Biotechnol.25(12), 1369–1372 (2007).
   PubMed Web of Science ®Google Scholar
• Stasi R . Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin. Biol. Ther.8(4), 527–540 (2008).
   PubMed Web of Science ®Google Scholar
• Hamann PR , HinmanLM, HollanderIet al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13(1), 47–58 (2002).
   PubMed Web of Science ®Google Scholar
• DiJoseph JF , GoadME, DougherMMet al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 10(24), 8620–8629 (2004).
   PubMed Web of Science ®Google Scholar
• DiJoseph JF , ArmellinoDC, BoghaertERet al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103(5), 1807–1814 (2004).
   PubMed Web of Science ®Google Scholar
• van der Neut Kolfschoten M , SchuurmanJ, LosenMet al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317(5844), 1554–1557 (2007).
   PubMed Web of Science ®Google Scholar
• Hamid O , SznolM, PavlickACet al. Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody–drug conjugate (ADC), in patients with advanced melanoma. J. Clin. Oncol. (Meeting Abstracts) 28(Suppl. 15), 8525 (2010).
   Web of Science ®Google Scholar
• Yoo EM , WimsLA, ChanLAet al. Human IgG2 can form covalent dimers. J. Immunol. 170(6), 3134–3138 (2003).
   PubMed Web of Science ®Google Scholar
• Ryan MC , HeringM, PeckhamDet al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol. Cancer Ther. 6(11), 3009–3018 (2007).
   PubMed Web of Science ®Google Scholar
• Desjarlais JR , LazarGA, ZhukovskyEAet al. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer‘s perspective. Drug Discov. Today 12(21–22), 898–910 (2007).
   PubMed Web of Science ®Google Scholar
• Lazar GA , DangW, KarkiSet al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103(11), 4005–4010 (2006).
   PubMed Web of Science ®Google Scholar
• Shields RL , LaiJ, KeckRet al. Lack offucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277(30), 26733–26740 (2002).
   PubMed Web of Science ®Google Scholar
• Shinkawa T , NakamuraK, YamaneNet al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278(5), 3466–3473 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster M , UmanaP, FerraraCet al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65(17), 7934–7941 (2005).
   PubMed Web of Science ®Google Scholar
• Lambert JM . Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol.5(5), 543–549 (2005).
   PubMed Web of Science ®Google Scholar
• Chari RV . Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Deliv. Rev.31(1–2), 89–104 (1998).
   PubMed Web of Science ®Google Scholar
• Chari RV , MartellBA, GrossJLet al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 52(1), 127–131 (1992).
   PubMed Web of Science ®Google Scholar
• Hinman LM , HamannPR, WallaceRet al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of anti-tumor antibiotics. Cancer Res. 53(14), 3336–3342 (1993).
   PubMed Web of Science ®Google Scholar
• Singh R , EricksonHK. Antibody-cytotoxic agent conjugates: preparation and characterization. In: Methods in Molecular Biology: Therapeutic Antibodies: Methods and Protocols525, 445–467 (2008).
   Google Scholar
• Baloglu E , MillerML, RollerEEet al. Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorg. Med. Chem. Lett. 14(23), 5885–5888 (2004).
   PubMed Web of Science ®Google Scholar
• Miller ML , RollerEE, WuXet al. Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies. Bioorg. Med. Chem. Lett. 14(15), 4079–4082 (2004).
   PubMed Web of Science ®Google Scholar
• Miller ML , RollerEE, ZhaoRYet al. Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery. J. Med. Chem. 47(20), 4802–4805 (2004).
   PubMed Web of Science ®Google Scholar
• Ojima I , GengX, WuXet al. Tumor-specific novel taxoid–monoclonal antibody conjugates. J. Med. Chem. 45(26), 5620–5623 (2002).
   PubMed Web of Science ®Google Scholar
• Burke PJ , SenterPD, MeyerDWet al. Design, synthesis, and biological evaluation of antibody–drug conjugates comprised of potent camptothecin analogues. Bioconjug. Chem. 20(6), 1242–1250 (2009).
   PubMed Web of Science ®Google Scholar
• Burke PJ , TokiBE, MeyerDWet al. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorg. Med. Chem. Lett. 19(10), 2650–2653 (2009).
   PubMed Web of Science ®Google Scholar
• Bross PF , BeitzJ, ChenGet al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7(6), 1490–1496 (2001).
   PubMed Web of Science ®Google Scholar
• Zein N , SinhaAM, McGahrenWJet al. Calicheamicin γ 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240(4856), 1198–1201 (1988).
   PubMed Web of Science ®Google Scholar
• DiJoseph JF , DougherMM, KalyandrugLBet al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin‘s B-cell lymphoma. Clin. Cancer. Res. 12(1), 242–249 (2006).
   PubMed Web of Science ®Google Scholar
• DiJoseph JF , KhandkeK, DougherMMet al. CMC-544 (inotuzumab ozogamicin): a CD22-targeted immunoconjugate of calicheamicin. Hematology Meeting Reports 5(6), 74–77 (2008).
   Google Scholar
• DiJoseph JF , DougherMM, ArmellinoDCet al. CD20-specific antibody-targeted chemotherapy of non-Hodgkin‘s B-cell lymphoma using calicheamicin-conjugated rituximab. Cancer Immunol. Immunother. 56(7), 1107–1117 (2007).
   PubMed Web of Science ®Google Scholar
• Boghaert ER , SridharanL, KhandkeKMet al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anticancer chemotherapy with calicheamicin. Int. J. Oncol. 32 (1), 221–234 (2008).
   PubMed Web of Science ®Google Scholar
• Hamann PR , HinmanLM, BeyerCFet al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts. Bioconjug. Chem. 16(2), 354–360 (2005).
   PubMed Web of Science ®Google Scholar
• MacMillan KS , BogerDL. Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065. J. Med. Chem.52(19), 5771–5780 (2009).
   PubMed Web of Science ®Google Scholar
• Chari RV , JackelKA, BourretLAet al. Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55(18), 4079–4084 (1995).
   PubMed Web of Science ®Google Scholar
• Tietze LF , KrewerB. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Chem. Biol. Drug Des.74(3), 205–211 (2009).
   PubMed Web of Science ®Google Scholar
• Tietze LF , KrewerB. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies. Anticancer Agents Med. Chem.9(3), 304–325 (2009).
   PubMed Web of Science ®Google Scholar
• Tietze LF , PankninO, KrewerBet al. Synthesis and biological evaluation of a novel pentagastrin–toxin conjugate designed for a targeted prodrug monotherapy of cancer. Int. J. Mol. Sci. 9(5), 821–837 (2008).
   PubMed Web of Science ®Google Scholar
• King D , TerrettJ, CardarelliPet al. Mechanism of activation of a human anti-cd70 antibody-mgba conjugate and efficacy in a nude rat model of renal carcinoma. AACR Meeting Abstracts (1 Annual Meeting 2008). 4057 (2008).
   Google Scholar
• Cardarelli P , KingD, TerrettJet al. Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate. AACR Meeting Abstracts (1 Annual Meeting 2008). 4061 (2008).
   Google Scholar
• Widdison WC , WilhelmSD, CavanaghEEet al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J. Med. Chem. 49(14), 4392–4408 (2006).
   PubMed Web of Science ®Google Scholar
• Lopus M , OroudjevE, WilsonLet al. Maytansine derivatives and metabolites of antibody–maytansinoid conjugates inhibit microtubule polymerization and strongly suppress microtubule dynamics. AACR Meeting Abstracts (1 Annual Meeting 2008). 1406 (2008).
   Google Scholar
• Oroudjev E , LopusM, WilsonLet al. Antibody–maytansinoid conjugates affect microtubule morphology and suppress microtubule dynamics in live cells. AACR Meeting Abstracts (1 Annual Meeting 2008). 1403 (2008).
   Google Scholar
• Remillard S , RebhunLI, HowieGAet al. Antimitotic activity of the potent tumor inhibitor maytansine. Science 189(4207), 1002–1005 (1975).
   PubMed Web of Science ®Google Scholar
• Drewinko B , PatchenM, YangLYet al. Differential killing efficacy of twenty anti-tumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res. 41(6), 2328–2333 (1981).
   PubMed Web of Science ®Google Scholar
• Murphy M , PhinneyS, AbOet al. Immunohistochemical analysis of the glycotope targeted by huC242-DM4 indicates strong expression in several tumor types with unmet medical need. AACR Meeting Abstracts (1 Annual Meeting 2008). 4898 (2008).
   Google Scholar
• Tolcher AW , OchoaL, HammondLAet al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a Phase I, pharmacokinetic, and biologic correlative study. J. Clin. Oncol. 21(2), 211–222 (2003).
   PubMed Web of Science ®Google Scholar
• Baeckstrom D , HanssonGC, NilssonOet al. Purification and characterization of a membrane-bound and a secreted mucin-type glycoprotein carrying the carcinoma-associated sialyl-Lea epitope on distinct core proteins. J. Biol. Chem. 266(32), 21537–21547 (1991).
   PubMed Web of Science ®Google Scholar
• Helft PR , SchilskyRL, HokeFJet al. A Phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin. Cancer Res. 10(13), 4363–4368 (2004).
   PubMed Web of Science ®Google Scholar
• Polson AG , YuSF, ElkinsKet al. Antibody–drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 110(2), 616–623 (2007).
   PubMed Web of Science ®Google Scholar
• Stephan JP , ChanP, LeeCet al. Anti-CD22–MCC–DM1 and MC–MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19(8), 1673–1683 (2008).
   PubMed Web of Science ®Google Scholar
• Mayo MF LA, Wang L, Wunderli P, Payne G, Xie H, Lutz RJ. In vivo stability in mice of SAR566658 (huDS6-DM4), an immunoconjugate targeting solid tumors. EORTC-NCI-AACR Proceedings (2008) (Abstract 533).
   Google Scholar
• Carrigan C , Zuany-AmorimC, MayoMFet al. Preclinical evaluation of SAR566658 (huDS6-DM4) in mice bearing human tumor xenografts of breast, ovarian, lung, cervical and pancreatic cancer. EORTC Meeting Abstracts Annual Meeting (2008) (Abstract 525).
   Google Scholar
• Bai R , PettitGR, HamelE. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem. Pharmacol.39(12), 1941–1949 (1990).
   PubMed Web of Science ®Google Scholar
• Doronina SO , TokiBE, TorgovMYet al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21(7), 778–784 (2003).
   PubMed Web of Science ®Google Scholar
• Doronina SO , MendelsohnBA, BoveeTDet al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug. Chem. 17(1), 114–124 (2006).
   PubMed Web of Science ®Google Scholar
• Gerber H -P, Kung-Sutherland M, Stone I et al. Potent anti-tumor activity of the anti-CD19 auristatin antibody–drug conjugate SGN-19A in rituximab sensitive and resistant lymphomas. EORTC Meeting Abstracts (2008) (Abstract 507).
   Google Scholar
• Gerber HP , Kung-SutherlandM, StoneIet al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12–vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113(18), 4352–4361 (2009).
   PubMed Web of Science ®Google Scholar
• Dornan D , BennettF, ChenYet al. Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti-CD79b–vcMMAE, for the treatment of non-Hodgkin lymphoma. Blood 114(13), 2721–2729 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson D , GooyaJ, MaoSet al. A human antibody–drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68(22), 9367–9374 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JW , HanHD, ShahzadMMet al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 101(17), 1193–1205 (2009).
   PubMed Web of Science ®Google Scholar
• Alley SC , BenjaminDR, JeffreySCet al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem. 19(3), 759–765 (2008).
   PubMed Web of Science ®Google Scholar
• Doronina SO , BoveeTD, MeyerDWet al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug. Chem. 19(10), 1960–1963 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L , AmphlettG, BlattlerWAet al. Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate, huN901–DM1, by mass spectrometry. Protein Sci. 14(9), 2436–2446 (2005).
   PubMed Web of Science ®Google Scholar
• Junutula JR , RaabH, ClarkSet al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26(8), 925–932 (2008).
   PubMed Web of Science ®Google Scholar
• Hamblett KJ , SenterPD, ChaceDFet al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10(20), 7063–7070 (2004).
   PubMed Web of Science ®Google Scholar
• McDonagh CF , TurcottE, WestendorfLet al. Engineered antibody–drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 19(7), 299–307 (2006).
   PubMed Web of Science ®Google Scholar
• Wu G , FangYZ, YangSet al. Glutathione metabolism and its implications for health. J. Nutr. 134(3), 489–492 (2004).
   PubMed Web of Science ®Google Scholar
• Mills BJ , LangCA. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochem. Pharmacol.52(3), 401–406 (1996).
   PubMed Web of Science ®Google Scholar
• Appenzeller-Herzog C , EllgaardL. The human PDI family: versatility packed into a single fold. Biochim. Biophys. Acta1783(4), 535–548 (2008).
   PubMed Web of Science ®Google Scholar
• Ciechanover A . Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Hematology Am. Soc. Hematol. Educ. Program1–12, 505–506 (2006).
   Google Scholar
• Hamann PR , HinmanLM, BeyerCFet al. An anti-CD33 antibody–calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13(1), 40–46 (2002).
   PubMed Web of Science ®Google Scholar
• Boghaert ER , KhandkeKM, Sridharan Let al. Determination of pharmacokinetic values of calicheamicin–antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples. Cancer Chemother. Pharmacol.61(6), 1027–1035 (2008).
   PubMed Web of Science ®Google Scholar
• Dowell JA , Korth-BradleyJ, LiuHet al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41(11), 1206–1214 (2001).
   PubMed Web of Science ®Google Scholar
• Kovtun YV , AudetteCA, MayoMFet al. Antibody–maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 70(6), 2528–2537 (2010).
   PubMed Web of Science ®Google Scholar
• Lutz RJ , XieH, WiddisonWCet al. HuC242-DM4, an antibody–maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice. AACR Meeting Abstracts2005(1), 334–335 (2005).
   Google Scholar
• Erickson HK , ParkPU, WiddisonWCet al. Antibody–maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66(8), 4426–4433 (2006).
   PubMed Web of Science ®Google Scholar
• Erickson H , WilhelmS, WiddisonWet al. Evaluation of the cytotoxic potencies of the major maytansinoid metabolites of antibody–maytansinoid conjugates detected in vitro and in preclinical mouse models. AACR Meeting Abstracts 2008 (Annual Meeting), 2150 (2008).
   Google Scholar
• Francisco JA , CervenyCG, MeyerDLet al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102(4), 1458–1465 (2003).
   PubMed Web of Science ®Google Scholar
• Okeley NM , MiyamotoJB, ZhangXet al. Intracellular activation of SGN-35, a potent anti-CD30 antibody–drug conjugate. Clin. Cancer Res. 16(3), 888–897 (2010).
   PubMed Web of Science ®Google Scholar
• Sanderson RJ , HeringMA, JamesSFet al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin. Cancer Res.11(2 Part 1), 843–852 (2005).
   PubMed Web of Science ®Google Scholar
• Walter RB , RadenBW, HongTCet al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 102(4), 1466–1473 (2003).
   PubMed Web of Science ®Google Scholar
• Linenberger ML , HongT, FlowersDet al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98(4), 988–994 (2001).
   PubMed Web of Science ®Google Scholar
• Leonard GD , FojoT, BatesSE. The role of ABC transporters in clinical practice. Oncologist8(5), 411–424 (2003).
   PubMed Web of Science ®Google Scholar
• Gottesman MM , PastanI. The multidrug transporter, a double-edged sword. J. Biol. Chem.263(25), 12163–12166 (1988).
   PubMed Web of Science ®Google Scholar
• Takara K , SakaedaT, OkumuraK. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des.12(3), 273–286 (2006).
   PubMed Web of Science ®Google Scholar
• Hamann PR , HinmanLM, BeyerCFet al. An anti-MUC1 antibody–calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug. Chem. 16(2), 346–353 (2005).
   PubMed Web of Science ®Google Scholar
• Guillemard V , Uri Saragovi H. Prodrug chemotherapeutics bypass P-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity. Oncogene23(20), 3613–3621 (2004).
   PubMed Web of Science ®Google Scholar
• Kovtun Y AC, Maloney E, Mayo M et al. Novel antibody–maytansinoid conjugates with improved efficacy against multidrug-resistant tumors. EORTC Proceedings (2008) (Abstract 518).
   Google Scholar
• DiJoseph JF , DougherMM, ArmellinoDCet al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21(11), 2240–2245 (2007).
   PubMed Web of Science ®Google Scholar
• Roepstorff K , GrovdalL, GrandalMet al. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem. Cell. Biol. 129(5), 563–578 (2008).
   PubMed Web of Science ®Google Scholar
• Tassone P , GozziniA, GoldmacherVet al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2´-deacetyl-N2´-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res.64(13), 4629–4636 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen M , BertholdF. Targeting the neural cell adhesion molecule in cancer. Cancer Lett.258(1), 9–21 (2007).
   PubMed Web of Science ®Google Scholar
• Whiteman KR , MurphyM.F, Cohane KP et al. Preclinical evaluation of IMGN901 (huN901-DM1) as a potential therapeutic for ovarian cancer. Am. Assoc. Clin. Res. Annu. Meet. (2008) (Abstract 2135).
   Google Scholar
• Roy DC , OuelletS, Le Houillier C et al. Elimination of neuroblastoma and small-cell lung cancer cells with an antineural cell adhesion molecule immunotoxin. J. Natl. Cancer Inst.88(16), 1136–1145 (1996).
   PubMedGoogle Scholar
• Fossella F , WollPJ, LoriganPet al. Investigation of IMGN901 in CD56+ solid tumors: results from a Phase I/II trial (study 001) and a Phase I trial (study 002). Presented at: The 13th World Conference on Lung Cancer. San Francisco, CA, USA, 31 July– 4 August 2009.
   Google Scholar
• Woll PJ , LoriganP, O‘BrienMet al. Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel-cell carcinoma (MCC). AACR-NCI-EORTC (2009) (Abstract B237).
   Google Scholar
• Thompson D , PatnaikA, BendellJet al. A Phase I dose-escalation study of IMGN388 in patients with solid tumors. J. Clin. Oncol. 28(15s) (2010) (Abstract 3058).
   Web of Science ®Google Scholar
• Aboukameel A , Goustin A-S, Mohammad R et al. Superior anti-tumor activity of the CD19-directed immunotoxin, SAR3419 to rituximab in non-Hodgkin‘s xenograft animal models: preclinical evaluation. ASH Annual Meeting Abstracts110, (2007) (Abstract 2339).
   Google Scholar
• Ikeda H , HideshimaT, LutzRJet al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has potent and selective cytotoxicity against cd138 positive multiple myeloma cells in vitro and in vivo. ASH Annual Meeting Abstracts. 112(11), 1716 (2008).
   Google Scholar
• Chanan-Khan AA , JagannathS, HeffnerLTet al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 114(22), 1862 (2009).
   Google Scholar
• Oflazoglu E , KisslerKM, SieversELet al. Combination of the anti-CD30–auristatin-E antibody–drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br. J. Haematol. 142(1), 69–73 (2008).
   PubMed Web of Science ®Google Scholar
• Hwu P , SznolM., Pavlick A. et al. A Phase I/II study of CRO-11–vcMMAE, an antibody–drug conjugate, in patients with unresectable stage III or stage IV melanoma. Am. Soc. Clin. Onc. Annu. Meet. Proc.9029 (2008).
   Google Scholar
• Sznol M , HamidO, HwuPet al. Pharmacokinetics (PK) of CR011–vcMMAE, an antibody–drug conjugate (ADC), in a Phase (Ph) I study of patients (pts) with advanced melanoma. J. Clin. Oncol. (Meeting Abstracts) 27(15S), 9063 (2009).
   Google Scholar
• Tse KF , JeffersM, PollackVAet al. CR011, a fully human monoclonal antibody–auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 12(4), 1373–1382 (2006).
   PubMed Web of Science ®Google Scholar
• Kantoff P , PetrylakDP, PomerantzMet al. First-in-human Phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer. J. Clin. Oncol. 28(15S), TPS245 (2010).
   Web of Science ®Google Scholar
• Tolcher AW , ForouzeshB, McCreeryHet al. A Phase I and pharmacokinetic study of BB-10901, a maytansinoid immunoconjugate, in CD56-expressing tumors. Presented at: The EORTC–NCI–AACR Symposium on Molecular Targets and Cancer Therapeutics (2005).
   Google Scholar
• Chanan-Khan AA , JagannathS, MunshiNCet al. Phase I study of huN901-DM1 (BB-10901) in patients with relapsed and relapsed/refractory CD56-positive multiple myeloma. ASH Annual Meeting Abstracts, Part 1. 110, 1174 (2007).
   Google Scholar
• McCann J , FossellaFV, Villalona-CaleroMAet al. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small-cell carcinoma. Am. Soc. Clin. Onc. Annu. Meet. Proc. 25, 18084 (2007).
   Google Scholar
• Giles F Morariu-Zamfir R, Lambert JM, Verstovsek S et al. Phase I study of AVE9633, an anti-CD33–maytansinoid immunoconjugate, administered as an intravenous infusion in patients with refractory/relapsed CD33-positive acute myeloid leukemia (AML). Am. Soc. Hematol. Annu. Meet. Proc. (2006).
   Google Scholar
• Larson RA , SieversEL, StadtmauerEAet al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg®) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104(7), 1442–1452 (2005).
   PubMed Web of Science ®Google Scholar
• Giles FJ . Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia. Expert Rev. Anticancer Ther.2(6), 630–640 (2002).
   PubMedGoogle Scholar
• Sauter A , KloftC, GronauSet al. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int. J. Oncol. 30(4), 927–935 (2007).
   PubMed Web of Science ®Google Scholar
• Rupp U , Schoendorf-HollandE, EichbaumMet al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a Phase I study. Anticancer Drugs 18(4), 477–485 (2007).
   PubMed Web of Science ®Google Scholar
• Tijink BM , ButerJ, de Bree R et al. A Phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res.12(20 Part 1), 6064–6072 (2006).
   PubMed Web of Science ®Google Scholar
• Riechelmann H , SauterA, GolzeWet al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 44(9), 823–829 (2008).
   PubMed Web of Science ®Google Scholar
• Heider KH , MulderJWR, OstermannEet al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur. J. Cancer 31(13–14), 2385 (1995).
   Google Scholar
• van der Velden VH , BoeckxN, JedemaIet al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia 18(5), 983–988 (2004).
   PubMed Web of Science ®Google Scholar
• Davies Q , PerkinsAC, FrierMet al. The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur. J. Nucl. Med. 24(2), 206–209 (1997).
   PubMedGoogle Scholar
• Baselga J , TripathyD, MendelsohnJet al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14(3), 737–744 (1996).
   PubMed Web of Science ®Google Scholar
• Pegram MD , LiptonA, HayesDFet al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16(8), 2659–2671 (1998).
   PubMed Web of Science ®Google Scholar
• Qin AW , WatermillJ, MasticoRAet al. The pharmacokinetics and pharmacoldynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors. Am. Soc. Clin. Onc. Annu. Meet. Proc. 3066 (2008).
   Google Scholar

Website

• Pfizer press release, 21 June 2010. www.pfizer.com/files/news/press_releases/2010/mylotarg_discontinuation_062110.pdf
   Google Scholar